BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 15120808)

  • 1. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.
    Gattis WA; O'Connor CM; Gallup DS; Hasselblad V; Gheorghiade M;
    J Am Coll Cardiol; 2004 May; 43(9):1534-41. PubMed ID: 15120808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure.
    Gattis WA; O'Connor CM
    Am J Cardiol; 2004 May; 93(9A):74B-6B. PubMed ID: 15144943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy C; Young JB;
    Am Heart J; 2007 Jan; 153(1):82.e1-11. PubMed ID: 17174643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications.
    Gattis WA; O'Connor CM; Gheorghiade M
    Rev Cardiovasc Med; 2002; 3 Suppl 3():S48-54. PubMed ID: 12447162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.
    Fonarow GC; Abraham WT; Albert NM; Gattis WA; Gheorghiade M; Greenberg B; O'Connor CM; Yancy CW; Young J
    Am Heart J; 2004 Jul; 148(1):43-51. PubMed ID: 15215791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure.
    Tarantini L; Cioffi G; Opasich C; Di Lenarda A; Pulignano G; Del Sindaco D; De Feo S; Stefenelli C; Russo P; Catania G
    Ital Heart J; 2004 Jun; 5(6):441-9. PubMed ID: 15320569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry.
    Franciosa JA; Massie BM; Lukas MA; Nelson JJ; Lottes S; Abraham WT; Fowler M; Gilbert EM; Greenberg B;
    Am Heart J; 2004 Oct; 148(4):718-26. PubMed ID: 15459606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study.
    Krantz MJ; Havranek EP; Haynes DK; Smith I; Bucher-Bartelson B; Long CS
    J Card Fail; 2008 May; 14(4):303-9. PubMed ID: 18474343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?
    Fowler MB
    Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
    Go AS; Yang J; Gurwitz JH; Hsu J; Lane K; Platt R
    Am J Cardiol; 2007 Aug; 100(4):690-6. PubMed ID: 17697830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carvedilol reduces aldosterone release in systolic heart failure.
    Aggarwal A; Wong J; Campbell DJ
    Heart Lung Circ; 2006 Oct; 15(5):306-9. PubMed ID: 16935558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study.
    Gheorghiade M; Gattis WA; Lukas MA; O'Connor CM;
    Am Heart J; 2003 Feb; 145(2 Suppl):S60-1. PubMed ID: 12594455
    [No Abstract]   [Full Text] [Related]  

  • 14. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure).
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB
    Am J Cardiol; 2008 Dec; 102(11):1524-9. PubMed ID: 19026308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
    Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
    Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
    Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
    J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
    N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
    Levy AR; Briggs AH; Demers C; O'Brien BJ
    Am Heart J; 2001 Sep; 142(3):537-43. PubMed ID: 11526370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
    Heitmann M; Davidsen U; Stokholm KH; Rasmussen K; Burchardt H; Petersen EB
    Scand J Clin Lab Invest; 2002; 62(2):97-104. PubMed ID: 12004934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.